Why the study?
Does enoxaparin reduce mortality and bleeding outcomes compared to unfractionated heparin in patients undergoing percutaneous coronary intervention?
Does enoxaparin reduce mortality and bleeding outcomes compared to unfractionated heparin in patients undergoing percutaneous coronary intervention?
Enoxaparin may offer a mortality and safety (bleeding) advantage over unfractionated heparin during PCI, especially in the setting of primary PCI for STEMI.
Enoxaparin may warrant preference over unfractionated heparin in PCI; confirms mortality and bleeding benefits in Level 1 meta-analysis.
Enoxaparin seems to be superior to unfractionated heparin in reducing mortality and bleeding outcomes during percutaneous coronary intervention and particularly in patients undergoing primary percutaneous coronary intervention for ST elevation myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Silvain et al. (2012) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: